MobiHealth News June 8, 2023
It is currently conducting an in-human trial of its diagnostic patch.
Diagnostics company Nutromics has raised A$11 million ($7 million) ahead of its Series A funding round later this year.
WHAT IT’S FOR
The company has been raising funds for the imminent commercialisation of its continuous diagnostic monitoring technology.
Established in 2017, Nutromics has been developing a “lab-in-a-patch,” which uses DNA sensor technology to track multiple targets, such as disease biomarkers and hard-to-dose drugs, in the human body. This technology is currently being tested in an in-human trial at Monash Health.
Aside from conducting clinical trials, the company is also setting up its R&D teams both in Australia and the United States.
THE LARGER TREND
The latest raise followed...